Cwm LLC Sells 13,589 Shares of Twist Bioscience Corporation $TWST

Cwm LLC decreased its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 83.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,683 shares of the company’s stock after selling 13,589 shares during the quarter. Cwm LLC’s holdings in Twist Bioscience were worth $99,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TWST. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the last quarter. GAMMA Investing LLC increased its stake in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Twist Bioscience by 8.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock valued at $222,000 after buying an additional 469 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its stake in Twist Bioscience by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 23,178 shares of the company’s stock valued at $910,000 after buying an additional 612 shares during the last quarter. Finally, Allianz Asset Management GmbH increased its stake in Twist Bioscience by 6.3% in the 1st quarter. Allianz Asset Management GmbH now owns 17,000 shares of the company’s stock valued at $667,000 after buying an additional 1,000 shares during the last quarter.

Insiders Place Their Bets

In related news, CAO Robert F. Werner sold 2,041 shares of Twist Bioscience stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $65,699.79. Following the completion of the transaction, the chief accounting officer directly owned 46,413 shares in the company, valued at approximately $1,494,034.47. The trade was a 4.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 31,348 shares of Twist Bioscience stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $1,009,092.12. Following the completion of the transaction, the chief executive officer owned 601,212 shares of the company’s stock, valued at $19,353,014.28. This represents a 4.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 64,368 shares of company stock worth $2,036,204 in the last three months. Insiders own 3.01% of the company’s stock.

Wall Street Analyst Weigh In

TWST has been the subject of several analyst reports. Evercore ISI decreased their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Finally, Barclays decreased their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Nine research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $48.56.

Twist Bioscience Trading Up 5.5%

Shares of TWST stock opened at $32.89 on Friday. The company has a 50 day moving average of $28.97 and a 200-day moving average of $31.87. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $24.07 and a 12-month high of $55.33. The firm has a market cap of $1.99 billion, a P/E ratio of -22.68 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.